U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C6H5O7.3K.H2O
Molecular Weight 324.4099
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of POTASSIUM CITRATE

SMILES

O.[K+].[K+].[K+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O

InChI

InChIKey=PJAHUDTUZRZBKM-UHFFFAOYSA-K
InChI=1S/C6H8O7.3K.H2O/c7-3(8)1-6(13,5(11)12)2-4(9)10;;;;/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);;;;1H2/q;3*+1;/p-3

HIDE SMILES / InChI

Molecular Formula K
Molecular Weight 39.0983
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula HO
Molecular Weight 17.0073
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C6H6O7
Molecular Weight 190.1076
Charge -2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including http://www.adm.com/en-US/worldwide/australia/Documents/Potassium%20Citrate%20AU.pdf | https://noshly.com/additive/e332/acidity-regulator-plus/332/#.WUp-1uvyjIU

Potassium citrate is indicated for the management of renal tubular acidosis with calcium stones, hypocitraturic calcium oxalate nephrolithiasis of any etiology, uric acid lithiasis with or without calcium stones. WhenPotassium citrate is given orally, the metabolism of absorbed citrate produces an alkaline load. The induced alkaline load in turn increases urinary pH and raises urinary citrate by augmenting citrate clearance without measurably altering ultrafilterable serum citrate. Thus, potassium citrate therapy appears to increase urinary citrate principally by modifying the renal handling of citrate, rather than by increasing the filtered load of citrate. Potassium citrate is used as a food additive (E 332) to regulate acidity.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
UROCIT-K

Approved Use

Urocit®-K is a citrate salt of potassium indicated for the management of: • Renal tubular acidosis (RTA) with calcium stones • Hypocitraturic calcium oxalate nephrolithiasis of any etiology • Uric acid lithiasis with or without calcium stones

Launch Date

1985
Primary
UROCIT-K

Approved Use

Urocit®-K is a citrate salt of potassium indicated for the management of: • Renal tubular acidosis (RTA) with calcium stones • Hypocitraturic calcium oxalate nephrolithiasis of any etiology • Uric acid lithiasis with or without calcium stones

Launch Date

1985
Doses

Doses

DosePopulationAdverse events​
540 mg 1 times / day multiple, oral
Recommended
Dose: 540 mg, 1 times / day
Route: oral
Route: multiple
Dose: 540 mg, 1 times / day
Co-administed with::
Thiamin oral 1.1 mg
Arginine oral 1240 mg
caffeine oral 52 mg
Sources: Page: p.2326
healthy, 24-59
n = 16
Health Status: healthy
Age Group: 24-59
Sex: M+F
Population Size: 16
Sources: Page: p.2326
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Comparative efficacy of "specific" potassium citrate therapy versus conservative management in nephrolithiasis of mild to moderate severity.
1985 Oct
Renal hypouricemia due to enhanced tubular secretion of urate associated with urolithiasis: successful treatment of urolithiasis by alkalization of urine K+, Na(+)-citrate.
1993
[Therapeutic use of potassium citrate].
2001
Evaluation of aggregating brain cell cultures for the detection of acute organ-specific toxicity.
2013 Jun
Patents

Sample Use Guides

In Vivo Use Guide
Objective: To restore normal urinary citrate (greater than 320 mg/day and as close to the normal mean of 640 mg/day as possible), and to increase urinary pH to a level of 6.0 to 7.0. • Severe hypocitraturia (urinary citrate < 150 mg/day): therapy should be initiated at 60 mEq per day; a dose of 30 mEq two times per day or 20 mEq three times per day with meals or within 30 minutes after meals or bedtime snack • Mild to moderate hypocitraturia (urinary citrate >150 mg/day): therapy should be initiated at 30 mEq per day; a dose of 15 mEq two times per day or 10 mEq three times per day with meals or within 30 minutes after meals or bedtime snack
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:32:08 GMT 2023
Edited
by admin
on Fri Dec 15 15:32:08 GMT 2023
Record UNII
EE90ONI6FF
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
POTASSIUM CITRATE
EP   FCC   GREEN BOOK   II   INCI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-IP  
INCI  
Official Name English
K-CIT-V
Brand Name English
POTASSIUM CITRATE, MONOHYDRATE
Systematic Name English
E-332(II)
Code English
ADV-7103 COMPONENT POTASSIUM CITRATE MONOHYDRATE
Common Name English
POTASSIUM CITRATE [USP-RS]
Common Name English
POTASSIUM CITRATE [II]
Common Name English
NSC-760107
Code English
INS NO.332(II)
Code English
POTASSIUM CITRATE [WHO-IP]
Common Name English
POTASSIUM CITRATE [ORANGE BOOK]
Common Name English
POTASSIUM CITRATE [FCC]
Common Name English
Tripotassium citrate monohydrate
Systematic Name English
POTASSIUM CITRATE [GREEN BOOK]
Common Name English
POTASSIUM CITRATE [USP MONOGRAPH]
Common Name English
ADV7103 COMPONENT POTASSIUM CITRATE MONOHYDRATE
Common Name English
POTASSIUM CITRATE MONOHYDRATE [MI]
Common Name English
1,2,3-PROPANETRICARBOXYLIC ACID, 2-HYDROXY-, TRIPOTASSIUM SALT, MONOHYDRATE
Common Name English
POTASSIUM CITRATE [VANDF]
Common Name English
POTASSIUM CITRATE [INCI]
Common Name English
Potassium citrate monohydrate [WHO-DD]
Common Name English
KALII CITRAS [WHO-IP LATIN]
Common Name English
INS-332(II)
Code English
UROCIT-K
Brand Name English
POTASSIUM CITRATE MONOHYDRATE [MART.]
Common Name English
POTASSIUM CITRATE [EP MONOGRAPH]
Common Name English
POTASSIUM CITRATE MONOHYDRATE
MART.   MI   WHO-DD  
Systematic Name English
Classification Tree Code System Code
JECFA EVALUATION INS-332(II)
Created by admin on Fri Dec 15 15:32:08 GMT 2023 , Edited by admin on Fri Dec 15 15:32:08 GMT 2023
EU-Orphan Drug EU/3/17/1888
Created by admin on Fri Dec 15 15:32:08 GMT 2023 , Edited by admin on Fri Dec 15 15:32:08 GMT 2023
FDA ORPHAN DRUG 2784
Created by admin on Fri Dec 15 15:32:08 GMT 2023 , Edited by admin on Fri Dec 15 15:32:08 GMT 2023
DSLD 2904 (Number of products:56)
Created by admin on Fri Dec 15 15:32:08 GMT 2023 , Edited by admin on Fri Dec 15 15:32:08 GMT 2023
CODEX ALIMENTARIUS (GSFA) INS-332(II)
Created by admin on Fri Dec 15 15:32:08 GMT 2023 , Edited by admin on Fri Dec 15 15:32:08 GMT 2023
NDF-RT N0000175896
Created by admin on Fri Dec 15 15:32:08 GMT 2023 , Edited by admin on Fri Dec 15 15:32:08 GMT 2023
CFR 21 CFR 184.1625
Created by admin on Fri Dec 15 15:32:08 GMT 2023 , Edited by admin on Fri Dec 15 15:32:08 GMT 2023
FDA ORPHAN DRUG 9785
Created by admin on Fri Dec 15 15:32:08 GMT 2023 , Edited by admin on Fri Dec 15 15:32:08 GMT 2023
NCI_THESAURUS C29730
Created by admin on Fri Dec 15 15:32:08 GMT 2023 , Edited by admin on Fri Dec 15 15:32:08 GMT 2023
WHO-ATC A12BA02
Created by admin on Fri Dec 15 15:32:08 GMT 2023 , Edited by admin on Fri Dec 15 15:32:08 GMT 2023
WHO-VATC QA12BA02
Created by admin on Fri Dec 15 15:32:08 GMT 2023 , Edited by admin on Fri Dec 15 15:32:08 GMT 2023
FDA ORPHAN DRUG 9685
Created by admin on Fri Dec 15 15:32:08 GMT 2023 , Edited by admin on Fri Dec 15 15:32:08 GMT 2023
FDA ORPHAN DRUG 913522
Created by admin on Fri Dec 15 15:32:08 GMT 2023 , Edited by admin on Fri Dec 15 15:32:08 GMT 2023
Code System Code Type Description
FDA UNII
EE90ONI6FF
Created by admin on Fri Dec 15 15:32:08 GMT 2023 , Edited by admin on Fri Dec 15 15:32:08 GMT 2023
PRIMARY
CHEBI
64746
Created by admin on Fri Dec 15 15:32:08 GMT 2023 , Edited by admin on Fri Dec 15 15:32:08 GMT 2023
PRIMARY
PUBCHEM
2735208
Created by admin on Fri Dec 15 15:32:08 GMT 2023 , Edited by admin on Fri Dec 15 15:32:08 GMT 2023
PRIMARY
DAILYMED
EE90ONI6FF
Created by admin on Fri Dec 15 15:32:08 GMT 2023 , Edited by admin on Fri Dec 15 15:32:08 GMT 2023
PRIMARY
RXCUI
221149
Created by admin on Fri Dec 15 15:32:08 GMT 2023 , Edited by admin on Fri Dec 15 15:32:08 GMT 2023
PRIMARY
CHEBI
64733
Created by admin on Fri Dec 15 15:32:08 GMT 2023 , Edited by admin on Fri Dec 15 15:32:08 GMT 2023
PRIMARY
ChEMBL
CHEMBL1200458
Created by admin on Fri Dec 15 15:32:08 GMT 2023 , Edited by admin on Fri Dec 15 15:32:08 GMT 2023
PRIMARY
CAS
6100-05-6
Created by admin on Fri Dec 15 15:32:08 GMT 2023 , Edited by admin on Fri Dec 15 15:32:08 GMT 2023
PRIMARY
DRUG CENTRAL
4519
Created by admin on Fri Dec 15 15:32:08 GMT 2023 , Edited by admin on Fri Dec 15 15:32:08 GMT 2023
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
POTASSIUM CITRATE
Created by admin on Fri Dec 15 15:32:08 GMT 2023 , Edited by admin on Fri Dec 15 15:32:08 GMT 2023
PRIMARY Description: Transparent crystals or a white, granular powder; odourless. Solubility: Freely soluble in water; practically insoluble in ethanol (~750 g/l) TS. Category: Systemic alkalinizing substance; component of oral rehydration salt mixtures. Storage: Potassium citrate should be kept in a tightly closed container. Additional information: Potassium citrate is deliquescent when exposed to moist air. Definition: Potassium citrate contains not less than 99.0% and not more than 101.0% of C6H5K3O7, calculated with reference tothe anhydrous substance.
NCI_THESAURUS
C29372
Created by admin on Fri Dec 15 15:32:08 GMT 2023 , Edited by admin on Fri Dec 15 15:32:08 GMT 2023
PRIMARY
WIKIPEDIA
POTASSIUM CITRATE
Created by admin on Fri Dec 15 15:32:08 GMT 2023 , Edited by admin on Fri Dec 15 15:32:08 GMT 2023
PRIMARY
DRUG BANK
DB09125
Created by admin on Fri Dec 15 15:32:08 GMT 2023 , Edited by admin on Fri Dec 15 15:32:08 GMT 2023
PRIMARY
EVMPD
SUB14973MIG
Created by admin on Fri Dec 15 15:32:08 GMT 2023 , Edited by admin on Fri Dec 15 15:32:08 GMT 2023
PRIMARY
MESH
D019357
Created by admin on Fri Dec 15 15:32:08 GMT 2023 , Edited by admin on Fri Dec 15 15:32:08 GMT 2023
PRIMARY
NSC
760107
Created by admin on Fri Dec 15 15:32:08 GMT 2023 , Edited by admin on Fri Dec 15 15:32:08 GMT 2023
PRIMARY
EPA CompTox
DTXSID8042501
Created by admin on Fri Dec 15 15:32:08 GMT 2023 , Edited by admin on Fri Dec 15 15:32:08 GMT 2023
PRIMARY
EVMPD
SUB75022
Created by admin on Fri Dec 15 15:32:08 GMT 2023 , Edited by admin on Fri Dec 15 15:32:08 GMT 2023
PRIMARY
MERCK INDEX
m9014
Created by admin on Fri Dec 15 15:32:08 GMT 2023 , Edited by admin on Fri Dec 15 15:32:08 GMT 2023
PRIMARY Merck Index
RS_ITEM_NUM
1548225
Created by admin on Fri Dec 15 15:32:08 GMT 2023 , Edited by admin on Fri Dec 15 15:32:08 GMT 2023
PRIMARY
RXCUI
54993
Created by admin on Fri Dec 15 15:32:08 GMT 2023 , Edited by admin on Fri Dec 15 15:32:08 GMT 2023
ALTERNATIVE
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY